Tempest Therapeutics, Inc. — Director's Dealing 2017

Mar 7, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2017-03-02

Reporting Person: Couturier Christophe (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-02	Stock Option (right to buy)	$1.49	A	45750	Acquired	2027-03-02	Common Stock (45750)	Direct

Footnotes

F1: The option vests as to 25% of the option shares on March 2, 2018 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter until March 2, 2021.